Trial Profile
Multicenter clinical trial, randomized, stratified, open and compared in patients with advanced NSCLC treated with Racotumomab or Nimotuzumab, vs Docetaxel after first line treatment oncospecific.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 14 Oct 2020
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Racotumomab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms RANIDO
- 11 Oct 2016 Results investigating racotumomab or nimotuzumab as a switch maintenance therapy in non progressor patients (n=237), presented at the 41st European Society for Medical Oncology Congress
- 29 Sep 2015 Results presented at the European Cancer Congress 2015
- 23 Jul 2014 New trial record